Zogenix (ZGNX) Given Daily News Sentiment Rating of 0.15
News headlines about Zogenix (NASDAQ:ZGNX) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Zogenix earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.6184371561554 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Zogenix (NASDAQ ZGNX) opened at $38.95 on Thursday. The company has a market capitalization of $1,330.00, a P/E ratio of -8.87 and a beta of 1.78. Zogenix has a 12 month low of $8.50 and a 12 month high of $43.35. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.23.
Several equities analysts have weighed in on ZGNX shares. BidaskClub cut Zogenix from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Mizuho reissued a “buy” rating and issued a $51.00 price target on shares of Zogenix in a research note on Wednesday, November 8th. ValuEngine raised Zogenix from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research raised Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, January 27th. Finally, JMP Securities assumed coverage on Zogenix in a research note on Monday, November 27th. They issued an “outperform” rating and a $56.00 price target for the company. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $42.67.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.